Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Capivasertib with Food and Acid Reducing Agents in Healthy Subjects
NCT04944771Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of capivasertib in Solid and hematological malignancies (12 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration at Day 3, Area Under the Curve to Infinity at Day 3 and 1 more. Started Jul 2021; status: completed.
02
Drugs
capivasertib
03
Conditions
Solid and hematological malignancies
Beyond the preview
Go deeper on NCT04944771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944771.